KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Total Current Liabilities (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Total Current Liabilities for 16 consecutive years, with $43.7 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 23.62% to $43.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $43.7 million through Dec 2025, up 23.62% year-over-year, with the annual reading at $43.7 million for FY2025, 23.62% up from the prior year.
  • Total Current Liabilities hit $43.7 million in Q4 2025 for Inovio Pharmaceuticals, down from $69.8 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $131.1 million in Q2 2022 to a low of $23.4 million in Q1 2024.
  • Historically, Total Current Liabilities has averaged $53.4 million across 5 years, with a median of $47.5 million in 2021.
  • Biggest five-year swings in Total Current Liabilities: crashed 60.38% in 2023 and later surged 197.13% in 2025.
  • Year by year, Total Current Liabilities stood at $65.7 million in 2021, then skyrocketed by 47.35% to $96.9 million in 2022, then crashed by 56.05% to $42.6 million in 2023, then fell by 17.02% to $35.3 million in 2024, then grew by 23.62% to $43.7 million in 2025.
  • Business Quant data shows Total Current Liabilities for INO at $43.7 million in Q4 2025, $69.8 million in Q3 2025, and $31.7 million in Q2 2025.